BREAKING NEWS
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Read full article: Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock dropEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter
Read full article: Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024
Read full article: Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year.